Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US

What is the association between the use of injectable depot medroxyprogesterone acetate and a meningioma diagnosis for women in the US?This population-based cohort study of a national US database demonstrated that women using depot medroxyprogesterone acetate had a statistically significant increased relative risk of developing a meningioma diagnosis when compared with women using oral medroxyprogesterone acetate, other contraceptives, and healthy controls without use of these contraceptives. No increased risk of meningioma diagnosis was found with any other contraceptive.In this study, women who used depot medroxyprogesterone acetate had an increased risk for developing a meningioma.

Corresponding Author: Varun R. Kshettry, MD, Skull Base, Pituitary kshettv@ccf.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.